Moderna Cash Flow from Operating Activities 2017-2025 | MRNA

Moderna cash flow from operating activities for the twelve months ending March 31, 2025 was $-10.133B, a 1.46% increase year-over-year.

  • Moderna annual cash flow from operating activities for 2024 was $-3.004B, a 3.66% decline from 2023.
  • Moderna annual cash flow from operating activities for 2023 was $-3.118B, a 162.6% decline from 2022.
  • Moderna annual cash flow from operating activities for 2022 was $4.981B, a 63.43% decline from 2021.

Moderna Cash Flow from Operating Activities 2017-2025 | MRNA

  • Moderna annual cash flow from operating activities for 2024 was $-3.004B, a 3.66% decline from 2023.
  • Moderna annual cash flow from operating activities for 2023 was $-3.118B, a 162.6% decline from 2022.
  • Moderna annual cash flow from operating activities for 2022 was $4.981B, a 63.43% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$217.3B
Amgen (AMGN)$160.8B
Gilead Sciences (GILD)$136.6B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$96B
CSL (CSLLY)$78.5B
GSK (GSK)$78.4B
Regeneron Pharmaceuticals (REGN)$59.2B
Alnylam Pharmaceuticals (ALNY)$42.1B
Argenex SE (ARGX)$35.4B
BioNTech SE (BNTX)$27B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.8B
Biogen (BIIB)$18.8B
Illumina (ILMN)$15.3B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$14B
Incyte (INCY)$13.4B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Exact Sciences (EXAS)$10.1B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.1B
Roivant Sciences (ROIV)$7.8B
Regencell Bioscience Holdings (RGC)$7.6B
Legend Biotech (LEGN)$7.3B